Methicillin-resistant Staphylococcus aureus pneumonia in adults

Expert Review of Respiratory Medicine

Volumn 8, Issue 5, 2014, Pages 641-651

  Woods, Christian ^a   Colice, Gene ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

community acquired pneumonia; hospital acquired pneumonia; linezolid; methicillin resistant Staphylococcus aureus; PantonValentine leukocidin; vancomycin; ventilator associated pneumonia

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; CHRONIC PATIENT; CLINICAL FEATURE; EARLY DIAGNOSIS; FLU LIKE SYNDROME; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PREVALENCE; REVIEW; COMMUNITY-ACQUIRED INFECTIONS; PNEUMONIA, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 84907055793     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.940323     Document Type: Review

References (92)

1. Martin CM, Kunin CM, Gottlieb LS, Finland M. Asian influenza A in Boston 1957-1958. II. Severe staphylococcal pneumonia complicating influenza. Arch Intern Med 1959;103(2):532-42
2. Schwarzmann SW, Adler LJ, Sullivan RJ Jr, Marine WM. Bacterial pneumonia during the Hong Kong influenza epidemic on 1968-1969. Arch Intern Med 1971;127(6): 1037-41
3. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(S5):S378-85
4. Hidron AI, Low CE, Honig EG, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotizing community-onset pneumonia. Lancet Infect Dis 2009;9(6): 384-92
5. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290(22):2976-84
6. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002;359(9308):753-9
7. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006;12(6):894-9
8. Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005;128(6):3854-62
9. Tadros M, Williams V, Coleman BL, et al. Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitals. PLoS One 2013;8(9):e75171
10. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010;23(3): 616-87
11. Huang H, Flynn NM, King JH, et al. Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, California. J Clin Microbiol 2006;44(7):2423-7
12. David MZ, Glikman D, Crawford SE, et al. What is community-associated methicillinresistant Staphylococcus aureus? J Infect Dis 2008;197(9):1235-43
13. Chua T, Moore CL, Perri MB, et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit. J Clin Microbiol 2008;46(7):2345-52
14. Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006;42(5): 647-56
15. Patel M, Kumar RA, Stamm AM, et al. USA300 genotype community-associated methicillin-resistant Staphylococcus aureus as a cause of surgical site infections. J Clin Microbiol 2007;45(10):3431-3
16. Patel M, Waites KB, Hoesley CJ, et al. Emergence of USA300 MRSA in a tertiary medical centre: implications for epidemiological studies. J Hosp Infect 2008; 68(3):208-13
17. Centers for Diseases Control and Prevention. Community associated MRSA information for clinicians. Infection control topics. Centers for Disease Control and Prevention, Atlanta, GA 2005. Available from www.cdc.gov/ncidod/dhqp/ar-mrsa-clinicians.html#4
18. Morrison MA, Hageman JC, Klevens RM. Case definition for community-associated methicillin-resistant Staphylococcus aureus. J Hosp Infect 2006;62(2):241
19. Klevens RM, Morrison MA, Nadle J, et al.Fridkin SK; Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298(15):1763-71
20. Van de Velde H. Étude sur la mécanisme de la virulence du staphylocoque pyogéne. Cellule. 1894;10:402-60
21. Panton PN, Came MB, Valentine FCO, Lond MRCP. Staphylococcal toxin. Lancet 1982;506-8
22. Holmes A, Ganner M, McGuane S, et al. Staphylococcus aureus isolates carrying Panton-Valentine leucocidin genes in England and Wales: Frequency, characterization, and association with clinical disease. J Clin Microbiol 2005; 43(5):2384-90
23. Diep BA, Sensabaugh GF, Somboonna N, et al. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J Clin Microbiol 2004;42(5):2080-4
24. Genestier AL, Michallet MC, Prévost G, et al. Staphylococcus aureus Panton-Valentine leukocidin directly targets mitochondria and induces Bax-independent apoptosis of human neutrophils. J Clin Invest 2005;115(11):3117-27
25. Lina G, Piémont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29(5):1128-32
26. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005;40(1):100-7
27. Voyich JM, Otto M, Mathema B, et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006;194(12):1761-70
28. Bubeck Wardenburg J, Bae T, Otto M, et al. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 2007;13(12):1405-6
29. Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, et al. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 2008;198(8):1166-70
30. Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007; 315(5815):1130-3
31. Hongo I, Baba T, Oishi K, et al. Phenol-soluble modulin alpha 3 enhances the human neutrophil lysis mediated by Panton-Valentine leukocidin. J Infect Dis 2009;200(5):715-23
32. Löffler B, Hussain M, Grundmeier M, et al. Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog 2010; 6(1):e1000715
33. Varshney AK, Martinez LR, Hamilton SM, et al. Augmented production of Panton-Valentine leukocidin toxin in methicillin-resistant and methicillin-susceptible Staphylococcus aureus is associated with worse outcome in a murine skin infection model. J Infect Dis 2010;201(1):92-6
34. Wooten DA, Winston LG. Risk factors for methicillin-resistant Staphylococcus aureus in patients with community-onset and hospital-onset pneumonia. Respir Med 2013;107(8):1266-70
35. Jung WJ, Kang YA, Park MS, et al. Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia. BMC Infect Dis 2013;13:370
36. Shorr AF, Myers DE, Huang DB, et al. A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infect Dis 2013;13(1): 268
37. DeRyke CA, Lodise TP Jr, Rybak MJ, McKinnon PS. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 2005;128(3):1414-22
38. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med 2008;168(20):2205-10
39. Monaco M, Antonucci R, Palange P, et al. Methicillin-resistant Staphylococcus aureus necrotizing pneumonia. Emerg Infect Dis 2005;11(10):1647-8
40. Thomas R, Ferguson J, Coombs G, Gibson PG. Community-acquired methicillin-resistant Staphylococcus aureus pneumonia: a clinical audit. Respirology 2011;16(6):926-31
41. Davies CW, Kearney SE, Gleeson FV, Davies RJ. Predictors of outcome and long-term survival in patients with pleural infection. Am J Respir Crit Care Med 1999;160:1682-7
42. Maskell N, Davies CW, Nunn A, et al. U. K. controlled trial of intrapleural streptokinase for pleural infections. N Engl J Med 2005;352(9):865-74
43. Maskell N, Batt S, Hedley EL, et al. The bacteriology of pleural fluid infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med 2006;174:817-23
44. Kollef MH. Diagnosis of ventilator-associated pneumonia. N Engl J Med 2006;355(25):2691-3
45. Seidenfeld JJ, Pohl DF, Bell RC, et al. Incidence, site, and outcome of infections in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1986;134(1): 12-16
46. Torres A, Martos A, Puig de la Bellacasa J, et al. Specificity of endotracheal aspiration, protected specimen brush, and bronchoalveolar lavage in mechanically ventilated patients. Am Rev Respir Dis 1993;147(4):952-7
47. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006;355(25):2619-30
48. Malhotra-Kumar S, Haccuria K, Michiels M, et al. MOSAR WP2 Study Team. Current trends in rapid diagnostics for methicillin-resistant Staphylococcus aureus and glycopeptide-resistant enterococcus species. J Clin Microbiol 2008; 46(5):1577-87
49. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011;52(3): 285-92
50. Morgan MS. Diagnosis and treatment of Panton-Valentine leukocidin (PVL)- associated staphylococcal pneumonia. Int J Antimicrob Agents 2007;30(4):289-96
51. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34(6):1589-96
52. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122(1):262-8
53. Mortensen EM, Restrepo M, Anzueto A, Pugh J. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004;117(10): 726-31
54. Kim SH, Park WB, Lee KD, et al. Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin Infect Dis 2003;37(6):794-9
55. Shorr AF, Combes A, Kollef MH, Chastre J . Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med 2006;34(3):700-6
56. Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29(5):1171-7
57. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38(5): 865-9
58. Scheetz MH, Wunderink RG, Postelnick MJ, Noskin GA. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 2006;26(4):539-50
59. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43(13):925-42
60. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006;130(4):947-55
61. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166(19):2138-44
62. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired Staphylococcus aureus importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005;128(4):2732-8
63. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42(6):2398-402
64. Woods CJ, Chowdhury A, Patel VM, Shorr AF. Impact of vancomycin minimum inhibitory concentration on mortality among critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2012;33(12):1246-9
65. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52(4): 1330-6
66. Jung YJ, Koh Y, Hong SB, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010;38(1):175-80
67. Rubinstein E, Cammarata S, Oliphant T, Wunderink R; Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU- 100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32(3):402-12
68. Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46(5):1475-80
69. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH; Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25(3):980-92
70. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124(5): 1789-97
71. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416
72. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54(5):621-9
73. Maclayton DO, Hall RG 2nd. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. Ann Pharmacother 2007;41(2):235-44
74. Mullins CD, Kuznik A, Shaya FT, et al. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Ther 2006;28(8):1184-98
75. Saravolatz L, Pawlak J, Johnson L. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010;54(7):3027-30
76. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010;51(6):641-50
77. Corey GR, Kollef MH, Shorr AF, et al. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother 2014. [Epub ahead of print]
78. Yum JH, Choi SH, Yong D, et al. Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea. Antimicrob Agents Chemother 2010; 54(12):5381-6
79. Schaadt R, Sweeney D, Shinabarger D, Zurenko G. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother 2009; 53(8):3236-9
80. Locke JB, Zurenko GE, Shaw KJ, Bartizal K. Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis 2014;58(Suppl 1):S35-42
81. Martínez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003;22(7):593-8
82. Kimura A, Mochizuki T, Nishizawa K, et al. Trimethoprim-sulfamethoxazole for the prevention of methicillin-resistant Staphylococcus aureus pneumonia in severely burned patients. J Trauma 1998; 45(2):383-7
83. Health Protection Agency PVL subgroup on the Steering Committee on Healthcare Associated Infection. Guidance on the diagnosis and management of PVL-associated Staphylococcus aureus infections (PVL-SA) in England. 2nd edition: 2008. Available from: www.hpa.org. uk/webc/HPAwebFile/HPAweb-C/1218699411960
84. Chastre J, Wolff M, Fagon JY, et al. PneumA Trial Group. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290(19): 2588-98
85. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994; 50(6 Pt 1):1545-9
86. Combes A, Luyt CE, Fagon JY, et al. PNEUMA Trial Group. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004;170(7):786-92
87. Athanassa Z, Siempos II, Falagas ME. Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review. Eur Respir J 2008;31(3):625-32
88. Hou M, Zhang N, Yang J, et al. Antimicrobial peptide LL-37 and IDR-1 ameliorate MRSA pneumonia in vivo. Cell Physiol Biochem 2013;32(3): 614-23
89. Robinson KM, McHugh KJ, Sivanarayana M, et al. Influenza A exacerbates Staphylococcus aureus pneumonia in mice by attenuating antimicrobial peptide production. J Infect Dis 2014;209:865-75
90. Ebert T, Smith S, Pancari G, et al. A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo. Hum Antibodies 2010;19(4):113-28
91. Varshney AK, Wang X, Scharff MD, et al. Staphylococcal Enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections. J Infect Dis 2013;208(12): 2058-66
92. Spaulding AR, Salgado-Pabón W, Merriman JA, et al. Vaccination against Staphylococcus aureus pneumonia. J Infect Dis 2014;209(12):1955-62